The designated quasi-drug “良朝丸,” supervised by Ryuji (リュウジ), will become available on a phased basis from 8 October at 1,855 マツキヨココカラ＆カンパニー stores nationwide, including マツモトキヨシ. The product’s manufacturer and its partner company announced the nationwide rollout.
P2C, a consolidated subsidiary of PIALA INC., announced the nationwide rollout of the designated quasi-drug “良朝丸,” supervised by culinary researcher Ryuji (リュウジ). Availability is scheduled to begin on a phased basis in October 2026 at 1,855 マツキヨココカラ＆カンパニー stores nationwide, expanding distribution from online-only channels to physical stores. This will make the product more readily accessible ahead of the year-end and New Year demand period. 良朝丸 has been sold through its official e-commerce site and major e-commerce marketplaces since its launch in December 2023, and began being sold in physical stores at ユニバーサルドラッグ in August 2026.
For the in-store rollout, the product will be offered in 2 pack sizes, 45 tablets (15 doses) and 135 tablets (45 doses), at approximately ¥88–¥99 per dose. The latest store information is available on the official e-commerce site, and some stores may carry different pack sizes. The product is described as containing the maximum amount of ursodeoxycholic acid, which supports liver function, together with turmeric powder and herbal ingredients, to relieve gastrointestinal discomfort and nausea associated with hangovers.